Skip to content

Evaluating the Effect of Flaxseed on PCOS

Evaluating the Effect of Flaxseed on Glycemic Indices, Lipid Profile, Hormones and Anthropometric Measurements on PCOS Patients

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20170916036204N8
Enrollment
84
Registered
2020-03-03
Start date
2020-01-20
Completion date
Unknown
Last updated
2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

poly-cystic ovarian syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: 30 grams of flax seed powder daily for 8 week in addition to weight loss diet and nutrition recommendations. Intervention 2: Control group: 30 grams of rice powder

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Diagnosis of Polycystic Ovarian Syndrome Based on Rotterdam Criteria By clinical practitioner

Exclusion criteria

Exclusion criteria: Family history of breast, ovarian or uterine cancer Alcohol or drug use Pregnancy or lactation Use of anti-hypertension and lipid lowering drugs Metformin use 6 months before enrollment and during the study Diabetes, thyroid disease or any systemic disease (eg kidney, liver, digestive system, cardiovascular) Other disorders that lead to increased androgens in the blood (such as Cushing's syndrome, hyper prolactinemia) Menopause Use of drugs that affect glucose metabolism

Design outcomes

Primary

MeasureTime frame
?Fasting Blood Sugar. Timepoint: At the beginning and the end of the study (after 8 weeks ). Method of measurement: FBS kit.;Insulin. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Insulin kit.

Secondary

MeasureTime frame
Luteinizing Hormone. Timepoint: At the beginning and the end of the study (after 8 weeks ). Method of measurement: Luteinizing Hormone kit.;Follicle-Stimulating Hormone. Timepoint: At the beginning and the end of the study (after 8 weeks ). Method of measurement: Follicle-Stimulating Hormone kit.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Moghdani

Shiraz University of Medical Sciences

zahra.moghdani@gmail.com+98 71 3725 1001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026